LD-2 disclosure · 4th Quarter - Amendment
PFIZER INC.
via PFIZER INC.
Client
- Name
- PFIZER INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- PFIZER INC.
- Description
- Biopharmaceuticals
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
5 issuesBudget/Appropriations
Appropriations
LobbyistsPAULA BURG
TargetedSENATE
Health Issues
Inflation Reduction Act (IRA) HR 7174 - Ensuring Pathways to Innovative Cures (EPIC) Act Medicare Price Setting Drug Shortages Global Access to Medicines Trade-Related Aspects of Intellectual Property Rights (IPR) March-in Framework Guidance and Policies S 79/ HR 1717 - Interagency Patent Coordination and Improvement Act of 2023 S 142 - Preserve Access to Affordable Generics and Biosimilars Act HR 6986 - To address patent thickets S 150 - Affordable Prescriptions for Patients Act of 2023 S 2780/ HR 5429 - Medication Affordability and Patent Integrity Act Antimicrobial Resistance PBM Transparency and Reform S 1542 - Delinking Revenue from Unfair Gouging (DRUG) Act S 3430 - Better Mental Health Care, Lower-Cost Drugs and Extenders Act S 2973 - Modernizing and Ensuring PMB Accountability Act 340B Reform HR 8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act
LobbyistsPAULA BURG · EMILY MUELLER · CATHERINE ROBINSON · ELISSA ALBEN · STEPHEN CLAEYS · FRANCISCO CARRILLO · MATTHEW STROIA · ms JENNIFER SWENSON WALTON · mrs ANGELA BOOTHE WILES
TargetedSENATE · HOUSE OF REPRESENTATIVES · White House Office · U.S. Trade Representative (USTR)
Medicare/Medicaid
S 723/HR 1458 - Access to Prescription Digital Therapeutics Act HR 8816 - American Medical Innovation and Investment Act of 2024
